Biotech CEO Podcast with William Wei Cao of Gracell Bio

Brian Yang interviews Nasdaq-listed cell therapy developer Gracell Bio Founder and CEO William Wei Cao who discussed the plan to enter the US market through quicker turnaround, faster delivery, cost-effective and safety profile. He also discussed taking the Shanghai-based firm’s CD19 and BCMA-dual targeted therapy to the first-line treatment, allogenic CAR-T therapies, combinations, Chinese biotech going global and surviving in the current “capital winter” environment.